Sands Capital Life Sciences Pulse Fund II, L.P. - Jun 30, 2025 SCHEDULE 13G/A Report for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share (IKT)

Filing Manager: Sands Capital Life Sciences Pulse Fund II, L.P.
Reporting Manager: Sands Capital Life Sciences Pulse Fund II, L.P.
Security: Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share
Symbol: IKT
Shares outstanding: 74.5M shares
Disclosed Ownership: 11M shares
Ownership: 14.7%
Form type: SCHEDULE 13G/A
Date filed: 8/13/2025, 11:17 AM
Date of event: Jun 30, 2025
SEC: View on sec.gov

Reporting Managers (3)

Name	Ownership	Shares Owned	shared voting power	Signature	Title
Sands Capital Life Sciences Pulse Fund II, L.P.	14.7%	11M	11M	/s/ Jonathan Goodman	Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P.
Sands Capital Alternatives, LLC	14.7%	11M	11M	/s/ Jonathan Goodman	Jonathan Goodman, General Counsel
SANDS FRANK M.	14.7%	11M	11M	/s/ Frank M. Sands	Frank M. Sands